Celularity Inc
For the period ended Jun 30, 2025. Filed Aug 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 29, 2025
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues | ||||
| Product sales, net | $2,379 | $9,963 | $11,397 | $22,806 |
| Services | 1,275 | 1,278 | 2,683 | 2,565 |
| License, royalty and other | 2,082 | 870 | 3,082 | 1,421 |
| Total net revenues | 5,736 | 12,111 | 17,162 | 26,792 |
| Operating expenses | ||||
| Cost of revenues (excluding amortization of acquired intangible assets) | ||||
| Product sales | 2,550 | 1,119 | 5,056 | 2,341 |
| Services | 220 | 537 | 429 | 714 |
| License, royalty and other | 2,472 | 467 | 3,311 | 708 |
| Research and development | 3,352 | 3,800 | 7,080 | 9,643 |
| Selling, general and administrative | 12,634 | 15,907 | 26,896 | 29,935 |
| Amortization of acquired intangible assets | 372 | 456 | 740 | 1,002 |
| Total operating expenses | 21,600 | 22,286 | 43,512 | 44,343 |
| Loss from operations | (15,864) | (10,175) | (26,350) | (17,551) |
| Other income (expense): | ||||
| Interest income | 62 | 67 | 138 | 177 |
| Interest expense | (1,943) | (1,552) | (4,380) | (2,700) |
| Change in fair value of warrant liabilities | (1,276) | 7,005 | (1,034) | (1,870) |
| Change in fair value of debt | (1,075) | (67) | (1,087) | 14 |
| Loss on debt extinguishment | — | — | (5,736) | (3,908) |
| Other expense, net | (4,428) | (1,766) | (5,829) | (2,663) |
| Total other (expense) income | (8,660) | 3,687 | (17,928) | (10,950) |
| Loss before income taxes | (24,524) | (6,488) | (44,278) | (28,501) |
| Income tax expense (benefit) | — | — | — | — |
| Net loss | $(24,524) | $(6,488) | $(44,278) | $(28,501) |
| Other comprehensive (loss) income | ||||
| Change in fair value of debt due to change in credit risk, net of tax | (3) | — | 2 | — |
| Comprehensive loss | $(24,527) | $(6,488) | $(44,276) | $(28,501) |
| Deemed dividend relating to inducement of Dragasac warrants | — | — | (64) | — |
| Net loss attributable to common shareholders | $(24,527) | $(6,488) | $(44,340) | $(28,501) |
| Share information: | ||||
| Net loss per share — basic and diluted | $(1.02) | $(0.30) | $(1.86) | $(1.32) |
| Weighted average shares outstanding — basic and diluted | 24,020,193 | 21,849,759 | 23,775,535 | 21,645,370 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.